A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010–2012

[1] Hainsworth JD(2006)Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study J Clin Oncol 24 3548-3554

[2] Spigel DR(2010)Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set Am J Surg Pathol 34 300-313

[3] Litchy S(2009)ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification Neuroendocrinology 90 162-166

[4] Greco FA(2001)The treatment of undifferentiated neuroendocrine tumors Crit Rev Oncol Hematol 37 47-51

[5] Klimstra DS(1999)Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin Br J Cancer 81 1351-1355

[6] Modlin IR(1991)Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer 68 227-232

[7] Adsay NV(2011)Current knowledge on diagnosis and staging of neuroendocrine tumors Cancer Metastasis Rev 30 3-7

[8] Chetty R(2012)First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience Acta Oncol 51 97-100

[9] Deshpande V(2012)Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas Sci World J 2012 170496-176

[10] Gönen M(2012)ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary Neuroendocrinology 95 157-363

[1] Hainsworth JD(2006)Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study J Clin Oncol 24 3548-3554

[2] Spigel DR(2010)Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set Am J Surg Pathol 34 300-313

[3] Litchy S(2009)ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification Neuroendocrinology 90 162-166

[4] Greco FA(2001)The treatment of undifferentiated neuroendocrine tumors Crit Rev Oncol Hematol 37 47-51

[5] Klimstra DS(1999)Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin Br J Cancer 81 1351-1355

[6] Modlin IR(1991)Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer 68 227-232

[7] Adsay NV(2011)Current knowledge on diagnosis and staging of neuroendocrine tumors Cancer Metastasis Rev 30 3-7

[8] Chetty R(2012)First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience Acta Oncol 51 97-100

[9] Deshpande V(2012)Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas Sci World J 2012 170496-176

[10] Gönen M(2012)ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary Neuroendocrinology 95 157-363